532372 Sigma-AldrichCdk7 Inhibitor VIII, THZ1 - Calbiochem
Cdk7 Inhibitor; THZ1
More>> Cdk7 Inhibitor; THZ1 Less<<Synonymes: (E)-N-(3-(5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide, 4HCl, THZ1, HCl
Produits recommandés
Aperçu
Replacement Information |
---|
Tableau de caractéristiques principal
Empirical Formula |
---|
C₃₁H₂₈ClN₇O₂ •4HCl |
Prix & Disponibilité
Référence | Disponibilité | Conditionnement | Qté | Prix | Quantité | |
---|---|---|---|---|---|---|
5.32372.0001 |
|
Flacon en verre | 10 mg |
|
— |
References | |
---|---|
References | Kwiatkowski, N., et al. 2014. Nature 511, 616. Chipumuro, E., et al. Cell 159, 1126. |
Product Information | |
---|---|
Form | Yellow solid |
Hill Formula | C₃₁H₂₈ClN₇O₂ •4HCl |
Chemical formula | C₃₁H₂₈ClN₇O₂ •4HCl |
Hygroscopic | Hygroscopic |
Reversible | N |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | Cdk7 |
Secondary target | Cdk12 |
Purity | ≥96% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Référence | GTIN |
5.32372.0001 | 04055977260083 |
Documentation
Cdk7 Inhibitor VIII, THZ1 - Calbiochem FDS
Titre |
---|
Cdk7 Inhibitor VIII, THZ1 - Calbiochem Certificats d'analyse
Titre | Numéro de lot |
---|---|
532372 |
Références bibliographiques
Aperçu de la référence bibliographique |
---|
Kwiatkowski, N., et al. 2014. Nature 511, 616. Chipumuro, E., et al. Cell 159, 1126. |
Brochure
Titre |
---|
NPI Flyer- Epigenetics and Nuclear Function Feature |
New Products - Antibodies, Small Molecule, Inhibitors |
Informations techniques
Titre |
---|
White Paper: Further considerations of antibody validation and usage. |